MedTrace Logo

Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

NCT02122822 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-11-17

No results posted yet for this study

Summary

RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.

PURPOSE: This trial is studying the safety and effectiveness of autologous gp96 treatment of glioblastoma and to see how well it works in treating patients with newly diagnosed supratentoria glioma.

Conditions

Interventions

BIOLOGICAL

gp96

vaccination of autologous gp96 derived from tumor tissue + basal treatment

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Cure&Sure Biotech Co., LTD

    lead INDUSTRY

Principal Investigators

  • Zhixian Gao, Doctor · Beijing Tiantan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-07-31
Completion
2017-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02122822 on ClinicalTrials.gov